Cotinga Pharmaceuticals (Cotinga Pharmaceuticals) FCF Margin % : 0.00% (As of Jan. 2020)

View and export this data going back to 2007. Start your Free Trial

What is Cotinga Pharmaceuticals FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Cotinga Pharmaceuticals's Free Cash Flow for the three months ended in Jan. 2020 was $-0.06 Mil. Cotinga Pharmaceuticals's Revenue for the three months ended in Jan. 2020 was $0.00 Mil. Therefore, Cotinga Pharmaceuticals's FCF Margin % for the quarter that ended in Jan. 2020 was 0.00%.

As of today, Cotinga Pharmaceuticals's current FCF Yield % is 0.00%.

The historical rank and industry rank for Cotinga Pharmaceuticals's FCF Margin % or its related term are showing as below:

COTQF's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -137.43
* Ranked among companies with meaningful FCF Margin % only.

Cotinga Pharmaceuticals FCF Margin % Historical Data

The historical data trend for Cotinga Pharmaceuticals's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cotinga Pharmaceuticals FCF Margin % Chart

Cotinga Pharmaceuticals Annual Data

Trend

Apr10

Apr11

Apr12

Apr13

Apr14

Apr15

Apr16

Apr17

Apr18

Apr19

FCF Margin %

Get a 7-Day Free Trial

Cotinga Pharmaceuticals Quarterly Data
	Apr15	Jul15	Oct15	Jan16	Apr16	Jul16	Oct16	Jan17	Apr17	Jul17	Oct17	Jan18	Apr18	Jul18	Oct18	Jan19	Apr19	Jul19	Oct19	Jan20
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Cotinga Pharmaceuticals's FCF Margin %

For the Biotechnology subindustry, Cotinga Pharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cotinga Pharmaceuticals's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cotinga Pharmaceuticals's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Cotinga Pharmaceuticals's FCF Margin % falls into.

Cotinga Pharmaceuticals FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Cotinga Pharmaceuticals's FCF Margin for the fiscal year that ended in Apr. 2019 is calculated as

FCF Margin	=	Free Cash Flow (A: Apr. 2019 )	/	Revenue (A: Apr. 2019 )
	=	-1.275	/	0
	=	%

Cotinga Pharmaceuticals's FCF Margin for the quarter that ended in Jan. 2020 is calculated as

FCF Margin	=	Free Cash Flow (Q: Jan. 2020 )	/	Revenue (Q: Jan. 2020 )
	=	-0.055	/	0
	=	%

Cotinga Pharmaceuticals FCF Margin % Related Terms

Thank you for viewing the detailed overview of Cotinga Pharmaceuticals's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Cotinga Pharmaceuticals (Cotinga Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cotinga Pharmaceuticals Inc (OTCPK:COTQF) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

82 Richmond Street East, The Canadian Venture Building, Toronto, ON, CAN, M5C1P1

Website

http://www.cotingapharma.com

Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.

Cotinga Pharmaceuticals (Cotinga Pharmaceuticals) Headlines

From GuruFocus

Cotinga Pharmaceuticals Reports Fiscal 2018 Third Quarter Financial and Operating Results

By GlobeNewswire GlobeNewswire • 04-03-2018

Cotinga Pharmacueticals Announces Closing of Unit Offering

By GlobeNewswire GlobeNewswire • 05-22-2019